Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea
2
조회
0
다운로드
14
인용
0
참고문헌
키워드
초록
Background/Aims: This nationwide, multicenter prospective randomized controlled trial aimed to compare the efficacy and safety of 10-day concomitant therapy (CT) and 10-day sequential therapy (ST) with 7-day clarithromycin-containing triple therapy (TT) as first-line treatment for Helicobacter pylori infection in the Korean population. Methods: Patients with H. pylori infection were assigned randomly to 7d-TT (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 7 days), 10d-ST (lansoprazole 30 mg and amoxicillin 1 g twice daily for the first 5 days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg twice daily for the remaining 5 days), or 10d-CT (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 10 days). The primary endpoint was eradication rate by intention-to-treat (ITT) and per-protocol (PP) analyses. Results: A total of 1,141 patients were included. The 10d-CT protocol achieved a markedly higher eradication rate than the 7d-TT protocol in both the ITT (81.2% vs 63.9%) and PP analyses (90.6% vs 71.4%). The eradication rate of the 10d-ST protocol was superior to that of the 7d-TT protocol (76.3% vs 63.9%, ITT analysis; 85.0% vs 71.4%, PP analysis). No significant differences in adherence or serious side effects were found among the three treatment arms. Conclusions: The 10d-CT and 10d-ST regimens were superior to the 7d-TT regimen as standard first-line treatment in Korea.
Abstract
Background/Aims: This nationwide, multicenter prospective randomized controlled trial aimed to compare the efficacy and safety of 10-day concomitant therapy (CT) and 10-day sequential therapy (ST) with 7-day clarithromycin-containing triple therapy (TT) as first-line treatment for Helicobacter pylori infection in the Korean population. Methods: Patients with H. pylori infection were assigned randomly to 7d-TT (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 7 days), 10d-ST (lansoprazole 30 mg and amoxicillin 1 g twice daily for the first 5 days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg twice daily for the remaining 5 days), or 10d-CT (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 10 days). The primary endpoint was eradication rate by intention-to-treat (ITT) and per-protocol (PP) analyses. Results: A total of 1,141 patients were included. The 10d-CT protocol achieved a markedly higher eradication rate than the 7d-TT protocol in both the ITT (81.2% vs 63.9%) and PP analyses (90.6% vs 71.4%). The eradication rate of the 10d-ST protocol was superior to that of the 7d-TT protocol (76.3% vs 63.9%, ITT analysis; 85.0% vs 71.4%, PP analysis). No significant differences in adherence or serious side effects were found among the three treatment arms. Conclusions: The 10d-CT and 10d-ST regimens were superior to the 7d-TT regimen as standard first-line treatment in Korea.
참고문헌 (46)
- Suerbaum S, "Helicobacter pylori infection", N Engl J Med, 347, pp.1175~1186 (2002)
- Graham DY, "Helicobacter pylori update : gastric cancer, reliable therapy, and possible benefits", Gastroenterology, 148, pp.719~731 (2015)
- Kavitt RT, "Management of Helicobacter pylori infection", JAMA, 317, pp.1572~1573 (2017)
- Asaka M, "Guidelines for the management of Helicobacter pylori infection in Japan : 2009 revised edition", Helicobacter, 15, pp.1~20 (2010)
- 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013", 대한소화기학회지, 62(1), pp.3~26 (2013), 대한소화기학회
- Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
- Gatta L, "Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy", BMJ, 347, pp.f4587~ (2013)
- Kim JM, "Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea", Antimicrob Agents Chemother, 48, pp.4843~4847 (2004)
- Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Thung I, "Review article : the global emergence of Helicobacter pylori antibiotic resistance", Aliment Pharmacol Ther, 43, pp.514~533 (2016)
- 김범진, "Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis", Journal of Korean Medical Science, 31(8), pp.1246~1253 (2016), 대한의학회
- Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
- Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use : nationwide survey", Helicobacter, 21, pp.266~278 (2016)
- Jung YS, "Efficacy of Helicobacter pylori eradication therapies in Korea : a systematic review and network meta-analysis", Helicobacter, 22, pp.e12389~ (2017)
- Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
- Chey WD, "ACG clinical guideline : treatment of Helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
- Graham DY, "Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies", Expert Rev Anti Infect Ther, 16, pp.679~687 (2018)
- Gisbert JP, "Review article : non-bismuth quadruple(concomitant)therapy for eradication of Helicobater pylori", Aliment Pharmacol Ther, 34, pp.604~617 (2011)
- Heo J, "A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication", Dig Liver Dis, 46, pp.980~984 (2014)
- Kim SY, "Comparative study of Helicobacter pylori eradication rates with 5-day quadruple"concomitant"therapy and 7-day standard triple therapy", J Clin Gastroenterol, 47, pp.21~24 (2013)
- Gatta L, "Sequential therapy or triple therapy for Helicobacter pylori infection : systematic review and meta-analysis of randomized controlled trials in adults and children", Am J Gastroenterol, 104, pp.3069~3079 (2009)
- Nyssen OP, "Sequential versus standard triple first-line therapy for Helicobacter pylori eradication", Cochrane Database Syst Rev, pp.CD009034~ (2016)
- Yeo YH, "First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance : a systematic review and network meta-analysis", Gut, 67, pp.20~27 (2018)
- Lee H, "Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea : study protocol for a randomized controlled trial", Trials, 18, pp.549~ (2017)
- Dueck AC, "Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events(PRO-CTCAE)", JAMA Oncol, 1, pp.1051~1059 (2015)
- Hsu PI, "Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection", Antimicrob Agents Chemother, 58, pp.5936~5942 (2014)
- 공은정, "Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change?", Journal of Korean Medical Science, 29(5), pp.704~713 (2014), 대한의학회
- Choe JW, "Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea", Helicobacter, 23, pp.e12466~ (2018)
- 김준성, "Sequential Therapy for Helicobacter pylori Infection in Korea: Systematic Review and Meta-Analysis", Gut and Liver, 7(5), pp.546~551 (2013), 거트앤리버 소화기연관학회협의회
- Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
- Graham DY, "New concepts of resistance in the treatment of Helicobacter pylori infections", Nat Clin Pract Gastroenterol Hepatol, 5, pp.321~331 (2008)
- Lee HJ, "Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies", World J Gastroenterol, 21, pp.351~359 (2015)
- Lee JW, "A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea", Scand J Gastroenterol, 49, pp.917~924 (2014)
- Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea : a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)
- Kefeli A, "Comparison of three different regimens against Helicobacter pylori as a first-line treatment : a randomized clinical trial", Bosn J Basic Med Sci, 16, pp.52~57 (2016)
- Webber MA, "The importance of efflux pumps in bacterial antibiotic resistance", J Antimicrob Chemother, 51, pp.9~11 (2003)
- Okada M, "A new quadruple therapy for Helicobacter pylori : influence of resistant strains on treatment outcome", Aliment Pharmacol Ther, 13, pp.769~774 (1999)
- Wu DC, "Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection", Clin Gastroenterol Hepatol, 8, pp.36~41 (2010)
- Vaira D, "Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication : a randomized trial", Ann Intern Med, 146, pp.556~563 (2007)
- Tong JL, "Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis", J Clin Pharm Ther, 34, pp.41~53 (2009)
- 이상욱, "Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis", Journal of Korean Medical Science, 30(8), pp.1001~1009 (2015), 대한의학회
- Georgopoulos S, "Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial", J Clin Gastroenterol, 47, pp.228~232 (2013)
- Park HG, "Randomised clinical trial : a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients", Aliment Pharmacol Ther, 35, pp.56~65 (2012)
- Choi HS, "Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection", World J Gastroenterol, 18, pp.2377~2382 (2012)
- Chung JW, "Ten-day sequential versus triple therapy for Helicobacter pylori eradication : a prospective, open-label, randomized trial", J Gastroenterol Hepatol, 27, pp.1675~1680 (2012)
- Oh HS, "Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea : a prospective, randomized study", J Gastroenterol Hepatol, 27, pp.504~509 (2012)